Press Release | Newsroom | Medtronic | Medtronic Wins U.S. Patent Case Against Gore Involving Stent Grafts

Press Release

Printer Friendly Version View printer-friendly version
Download PDF Download PDF
<< Back
Medtronic Wins U.S. Patent Case Against Gore Involving Stent Grafts

MINNEAPOLIS –– June 27, 2012 –– Medtronic, Inc. (NYSE: MDT) announced today that a judge in the Eastern District Court of Virginia last week ruled in Medtronic’s favor in a patent case brought by W.L Gore & Associates, Inc.

The patent in question involved a method of making stent grafts, which are implantable medical devices used to treat aortic aneurysms. The judge determined that Medtronic’s stent grafts did not infringe Gore’s U.S. Patent No. 5,810,870.

“We’re pleased with the court’s decision,” said Tony Semedo, vice president and general manager for the Endovascular Therapies at Medtronic, “which enables us to continue our focus on advancing the standard of care for the endovascular repair of aortic aneurysms. In that context, respect for intellectual property remains a core principle that we continuously and vigorously defend. ”

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

Medtronic, Inc. (, headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

– end –

Medtronic Media Contacts:
Joe McGrath, Public Relations, 707-591-7367
Jeff Warren, Investor Relations, 763-505-2696